10Y UST4.74%+1.07%30Y MTG6.65%-0.30%SOFR3.65%VNQ$98.88-0.22%XLRE$45.25-0.18%FED FUNDS3.63%
Real Estate Trail
Institutional Press Wire
PR Newswire

Afecta Pharmaceuticals Granted New US Patent for Neuro-Immuno Modulators

Via PR Newswire · August 25, 2026
Compiled by Real Estate Trail Editorial · August 25, 2026

Why this matters

Commercial real estate continues to digest a multi-year reset in cost of capital. Transaction velocity is below the 2019-2021 trend but improving, cap rates have stabilized across most stabilized property types, and the bid-ask gap has narrowed materially in the past two quarters. Sponsors with permanent capital and operating platforms have an advantage in the current execution environment. The next twelve months will continue to reward underwriting discipline and operational sophistication over balance-sheet aggression.

Editorial analysis · Real Estate Trail Editorial

Excerpt from PR Newswire:
IRVINE, Calif., Aug. 25, 2026 /PRNewswire/ -- Afecta Pharmaceuticals, focused on developing breakthrough multi-target therapies for complex disorders announced that USPTO has granted the company a new patent entitled…
Read the full article at PR Newswire

External link. Real Estate Trail does not republish source content.

More from the wire

Hospitality Net · Hospitality

Building a Hotel Food & Beverage Budget that Performs

An eight-step framework for hotel F&B leaders building 2027 budgets, covering revenue planning, labor deployment, food and beverage cost control, capital investment, and contingency planning.

23m ago